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Tumour–node–metastasis (TNM) staging is the most frequently
used prognostic tool in carcinoma of the gallbladder. Risk strati-
fication within the T2/T3 N0 and N1 stages in resected gallbladder
cancer may help in planning postoperative adjuvant therapy.
Certain molecular markers have been used to predict prognosis
in resectable gallbladder carcinoma, including Tp53 and K-Ras
mutations. The results, however, have been variable, and have
not yielded clear clinical relevance.1 Other histochemical markers
have been described, including RCAS1 (receptor-binding cancer
antigen expressed on SiSo cells),2 epithelial cell adhesion molecule
(Ep-CAM) overexpression3 and the combined expression status of
Skp2 and Ki-67. Cyclin D1 overexpression is reported to be an
independent negative prognostic factor in gallbladder cancer.4
This issue of HPB carries an article by Nagano and colleagues,
of Miyazaki University School of Medicine, correlating nuclear
expression of thioredoxin-1 (Trx-1) in the tumour invasion front
with outcome in resected gallbladder carcinoma.5 Thioredoxins
are ubiquitous proteins containing a conserved -Trp-Cys-Gly-
Pro-Cys-Lys- redox catalytic site. Thioredoxin is reduced by
NADPH (nicotinamide adenine dinucleotide phosphate-oxidase)
and Trx reductase (Trx-Red) by the oxidizing of cysteine groups
on proteins. When Trx levels are elevated, there is increased cell
growth, resistance to the normal mechanisms of apoptosis and
resistance to chemotherapy.4 An increase in Trx levels is seen in
many human primary cancers compared with normal tissue.
Thioredoxin can increase cell growth by increasing cellular sup-
plies of reducing equivalents for DNA synthesis, activating tran-
scription factors that regulate cell growth, and increasing the
sensitivity of cells to extracellular cytokines and growth factors.
Aggressive tumours overexpress both Trx and Trx-Red. Conse-
quently, such tumours have high proliferation capacities, low apo-
ptosis rates and elevated metastatic potential.6
Nagano et al. used archival samples for immunohistochemical
staining for Trx-1 and Trx-Red, focusing on different regions of
the tumour.5 They describe the ‘invasion front’ as the interface
between the deepest tumour edge and normal tissue. Use of the
invasion front of a tumour as a prognostic tool has also been
described in oral cancers.6
That Trx-1 is increased in gallbladder tumours compared
with cholecystitis specimens is predictable. However, the critical
finding of the study is that increased levels of Trx-1 in the invasion
front indicate a worse prognosis.5 The analysis is based on four
samples with Trx-1 nuclear expression in the tumour front alone
and nine samples with Trx-1 expression in both the front and
centre of the tumour. The samples were accrued during 1990–
2006, which represents a lengthy period notable for the different
strategies applied in the management of gallbladder carcinoma
worldwide. The conclusion is based on univariate analysis, which
included several standard prognostic variables. Naturally, the
prognostic significance of Trx-1 expression needs to be confirmed
in a larger sample size and with multivariate analysis. Although
Trx-Red can follow the expression pattern of Trx-1 in cancers,7
Trx-Red was not found to be statistically significant in this study.5
The heterogeneity of tumours is well established and, in
essence, reflects their deadly biology. In a landmark publication
in March 2012, Gerlinger and colleagues identified remarkable
heterogeneity within a single tumour.8 They obtained tumour
samples before and after treatment and took multiple samples
from each patient’s primary and metastatic tumour sites. About
two thirds of the mutations found in single biopsies were not
uniformly detectable throughout all sampled regions of the same
tumour. A ‘favourable prognosis’ gene profile and an ‘unfavour-
able prognosis’ gene profile were expressed in different regions of
the same tumour. Thus, a single-site tumour analysis cannot be
considered representative of the landscape of genomic abnormali-
ties in any tumour.8 What might the molecular profiling of gall-
bladder carcinoma offer tomorrow? Will we be able to identify a
reliable molecular signature for this disease that can guide treat-
ment strategies and stratify prognosis? Tissue microarrays and
other molecular analyses will accelerate studies associating novel
molecular discoveries using genomics, proteomics and metabolo-
mics.9 In gallbladder cancer and other tumours, the involvement
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of the Trx system in oncogenesis and tumorigenesis may someday
make it a target for novel anticancer therapies. Until that day
arrives, however, TNM staging remains the best option for prog-
nosis and treatment planning in gallbladder carcinoma.
References
1. Hidalgo Grau LA, Badia JM, Salvador CA, Monsó TS, Canaleta JF, Nogués
JM et al. (2004) Gallbladder carcinoma: the role of p53 protein overexpres-
sion and Ki-67 antigen expression as prognostic markers. HPB 6:174–180.
2. Oshikiri T, Hida Y, Miyamoto M, Hashida H, Katoh K, Suzuoki M et al.
(2001) RCAS1 as a tumour progression marker: an independent negative
prognostic factor in gallbladder cancer. Br J Cancer 85:1922–1927.
3. Varga M, Obrist P, Schneeberger S, Mühlmann G, Felgel-Farnholz C, Fong
D et al. (2004) Overexpression of epithelial cell adhesion molecule antigen
in gallbladder carcinoma is an independent marker for poor survival. Clin
Cancer Res 10:3131–3136.
4. Hui AM, Li X, Shi YZ, Takayama T, Torzilli G, Makuuchi M. (2000) Cyclin D1
overexpression is a critical event in gallbladder carcinogenesis and
independently predicts decreased survival for patients with gallbladder
carcinoma. Clin Cancer Res 6:4272–4277.
5. Nagano M, Hatakeyama K, Kai M, Nakamura H, Yodoi J et al. (2012)
Nuclear expression of thioredoxin-1 in the invasion front is associated
with outcome in patients with gallbladder carcinoma. HPB 14:573–
582.
6. Powis G, Mustacich D, Coon A. (2000) The role of the redox protein
thioredoxin in cell growth and cancer. Free Radic Biol Med 29:312–
322.
7. Lincoln DT, Ali Emadi EM, Tonissen KF, Clarke FM. (2003) The thioredoxin-
thioredoxin reductase system: over-expression in human cancer. Antican-
cer Res 23:2425–2433.
8. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E
et al. (2012) Intratumour heterogeneity and branched evolution revealed by
multiregion sequencing. N Engl J Med 366:883–892.
9. Nocito A, Kononen J, Kallioniemi OP, Sauter G. (2001) Tissue microarrays
(TMAs) for high-throughput molecular pathology research. Int J Cancer
94:1–5.
572 HPB
HPB 2012, 14, 571–572 © 2012 International Hepato-Pancreato-Biliary Association
